Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn's Disease.
Fiche publication
Date publication
novembre 2021
Journal
Gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, Hirai F, D'Haens G, Belin RM, Miller D, Gomez-Valderas E, Naegeli AN, Tuttle JL, Pollack PF, Sandborn WJ
Lien Pubmed
Résumé
Mirikizumab is a humanized monoclonal antibody targeting IL-23p19 with demonstrated efficacy in psoriasis and ulcerative colitis. We investigated the safety and efficacy of mirikizumab in patients with moderate-to-severe Crohn's disease (CD).
Mots clés
IBD, cytokine, inhibitor
Référence
Gastroenterology. 2021 Nov 5;: